Companies › Apollomics
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| APL-101 MET inhibitor | MET | Phase 2 | Solid Tumors; Metastatic Non Small Cell Lung Cancer | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03175224 | APL-101 | Phase 2 | Solid Tumors | Oncology | Nov 2026 |
| NCT04743505 | APL-101 | Phase 1 | Metastatic Non Small Cell Lung Cancer | Oncology | Jan 2027 |
Abion Beijing Pearl Biotechnology Limited Liability Company Beijing Scitech-Mq Pharmaceuticals Shanghai Guangsheng Biopharmaceutical VIVUS
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.